Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease

Upworthy

02 Jul 2021 0 shares 1 views

Upworthy

Published 02 Jul 2021

Efficacy analysis demonstrates COVAXIN™ to be 93.4% protective against severe symptomatic COVID-19Efficacy data demonstrates 65.2%...

Covaxin has overall vaccine efficacy of 77.8%, claims Bharat Biotech in results from Phase 3 trials

Covaxin showed 65.2% protection against the Delta variant (B.1.617.2) of COVID-19.

Zee News 03 Jul 2021

Ocugen (OCGN)+13.3% post-market after Indian co-development partner Bharat Biotech shared "positive results" of its Phase 3 study..

Upworthy 02 Jul 2021